Arbutus Biopharma is an interesting stock. There's a lot to know about it.
First of all they are trying to find a functional cure of HepB, this is called AB-729 and it is in the late stage 1 trials. They have announced results from a single dose study which were VERY positive and we are awaiting results from multi-dose part of the trial which should be announced...
Fib level as of what i see now at .786 looks to be right here. its also where prior resistance may turn into support for the price. also the 200 sma has had time to catch up to the price of the stock and can be another indicator for the patient people on the sidelines that the chart has leveled off for now.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of...
Bullish golden cross
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
ABUS broke the resistance line and floating over the support line. Expecting a line comeback to support line or ex-resistance-new-support line (they might converge) to fuel up before the big leap. A touch on the midline would be enough to get on the train.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.